Cassava Sciences reported $8.98M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
Abbott USD 3.09B 39M Jun/2025
Amgen USD 1.69B 4M Jun/2025
Biogen USD 583.8M 11.3M Jun/2025
Cassava Sciences USD 8.98M 23K Jun/2025
Eisai JPY 100.16B 6.34B Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
Geron USD 38.56M 1.46M Jun/2025
J&J USD 5.89B 777M Jun/2025
Merck USD 2.63B 104M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Roche Holding CHF 3.61B 381M Dec/2024